Martinsried/Munich, February 26 2013. Medigene AG (Frankfurt, Prime Standard) announced today that Veregen® was included into the 2012 European Guideline for the Management of Anogenital Warts. This internationally accepted treatment guideline, developed by clinical experts, recommends Veregen® (Sinecatechins 10% & 15% ointment) as a treatment option for genital warts. The guideline will be published in the March 2013 edition of the "Journal of the European Academy of Dermatology and Venereology"*, and is already available online. The inclusion of Veregen® into the treatment guidelines in other countries is in preparation.
Since 2010, Veregen® (Sinecatechins 15% ointment) has also been recommended as a treatment option for genital warts in the US Department of Health and Human Services Center for Disease Control and Prevention's Sexually Transmitted Diseases Treatment Guidelines.
"We are pleased that Veregen® is being endorsed as an efficacious and safe treatment in both the US and the European treatment guidelines. These guidelines represent an important source of key information for physicians for the treatment of this extremely onerous sexually transmitted disease", commented Dr. Frank Mathias, CEO of Medigene AG.
About Veregen®: Veregen® is a topical treatment for external genital warts, which contains a concentrate of catechins with a complex defined composition extracted from green tea leaves. Veregen® is already marketed in the USA (by Fougera), Germany, Austria and Switzerland (by Abbott), and Spain (by Bial). Marketing authorizations in additional countries have been granted or are expected within the next few months. Medigene has entered into several marketing partnerships for Veregen across Europe, Asia, and America, and is planning to continue this global licensing strategy to further exploit the market potential of Veregen®.
Medigene AG (Frankfurt: MDG, prime standard) is a publicly listed biotechnology company headquartered in Martinsried/Munich, Germany. Medigene focuses on clinical research and development of novel drugs against cancer and autoimmune diseases. Medigene was the first German biotech company to have revenues from marketed products, which are distributed by partner companies. It has two drug candidates in clinical trials, EndoTAG®-1 and RhuDex®, and is developing an innovative vaccine technology. For more information, please visit www.medigene.com.
*Journal of the European Academy of Dermatology and Venerology, Volume 27, Issue 3, March 2013, Pages e263-e270, C.J.N. Lacey, S.C.Woodhall, A.Wikstrom and J.Ross
This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® and Veregen® are registered trademarks of Medigene AG. Polyphenon E® is a trademark of Mitsui Norin Co., Ltd. These trademarks may be owned or licensed in select locations only.
Julia Hofmann, Claudia Burmester
Investor & Public Relations
ph.: +49 - 89 - 20 00 33 - 33 01
To unsubscribe from the press release distribution list, please go to www.medigene.com/unsubscribe.